Blood · 2004 · 320 citations · 51 references
MedicineHematologyImmunologyStem Cell TransplantationTransplant ImmunologyConditioning RegimensDonor MatchingDonor-recipient CompatibilityHematopoietic Stem Cell TransplantationHistocompatibilityHla MatchingHematopoietic Stem Cell Transplant ConditioningHla Matching In TransplantationHla-dp MatchingNon-myeloablative ConditioningNonmyeloablative ConditioningStem Cell Donor MatchingTransplantation Outcome Assessment
Nonmyeloablative regimens for allogeneic hematopoietic cell transplantation (HCT) have been developed for patients ineligible for myeloablative conditioning. We compared regimen-related toxicities (RRTs) and nonrelapse mortality (NRM) in 73 nonmyeloablative and 73 myeloablative recipients of HLA-matched related donor HCT, using the National Cancer Institute (NCI) Common Toxicity Criteria. Nonmyeloablative regimens were 2 Gy total body irradiation (TBI), either alone (n = 40) or combined with fludarabine, 30 mg/m(2)/d for 3 days (n = 33). Posttransplantation immunosuppression included mycophenolate mofetil and cyclosporine. Myeloablative regimens consisted mostly of cyclophosphamide + TBI or busulfan + cyclophosphamide, followed by posttransplantation methotrexate and cyclosporine. Nonmyeloablative patients were at higher risk than ablative patients because of greater age, longer time from diagnosis to HCT, more frequent preceding high-dose HCT, and higher pretransplantation Charlson comorbidity scores. Nevertheless, they experienced significantly less severe toxicities in 7 organs/systems: hematologic, gastrointestinal, hepatic, hemorrhage, infection, metabolic, and pulmonary. This translated into less NRM at day 100 (3% versus 23%, P = 10(-4)) and 1 year (16% versus 30%, P =.04). In multivariate analysis, the strongest factor predicting lessened RRT and NRM was nonmyeloablative conditioning, whereas high pretransplantation comorbidity scores predicted higher NRM. In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores.
51
Validation of a combined comorbidity index
Mary E. Charlson, Ted P. Szatrowski, Janey C. Peterson et al. · Journal of Clinical Epidemiology · 1994 · 6.6K citations
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Statistical Models Based on Counting Processes
Xavier Bry, Per Kragh Andersen, Ørnulf Borgan et al. · Population · 1997 · 2.9K citations
Shimon Slavin, Arnon Nagler, E Naparstek et al. · Blood · 1998 · 1.9K citations · Full text
Medicine, Hematology, Oncology +17